Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
:YMAB
YMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.55 - $16.11
Previous CloseN/A
Volume43.26K
Average Volume (3M)183.19K
Market Cap
$219.23M
Enterprise Value$131.44M
Total Cash (Recent Filing)$60.31M
Total Debt (Recent Filing)$603.00K
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 07, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding45,295,795
10 Day Avg. Volume144,417
30 Day Avg. Volume183,192
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)2.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.00
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue0.38
Enterprise Value/Gross Profit1.81
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$13.86Price Target Upside188.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Y-Mabs Therapeutics News
PremiumCompany Announcements
Y-Mabs Therapeutics Elects New Director at Annual Meeting
PremiumCompany Announcements
Y-Mabs Therapeutics Updates on Radiopharmaceutical ProgressBulls Say, Bears Say
Bulls Say
Clinical TrialsManagement disclosed results from Part A of the ongoing Phase 1/2 trial, demonstrating tumor uptake of 177 in all nine patients with positive GD2 expression.
InnovationY-mAbs has chosen to transition to a new proprietary radiohapten, expanding access to a range of isotopes with theranostic applications.
Product DevelopmentY-mAbs Therapeutics is noted as the only company with pretargeting assets already in the clinic, which could lead to differentiated next-generation radiopharmaceutical products.
Bears Say
Optimization NeedsThe optimization to both formulation and linker is needed given that they did not reach the optimal therapeutic index.
Therapeutic Index ChallengesThe results for GD2-SADA show that further optimization is required, as no cohort demonstrated an optimal therapeutic index.
TimelinesTimelines for execution of clinical trials has remained a sticking point for investors.
Ownership Overview
17.08% Insiders
7.96% Mutual Funds
0.10% Other Institutional Investors
66.15% Public Companies and
Individual Investors
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Y-Mabs Therapeutics lowest stock price was $3.55 and its highest was $16.11 in the past 12 months.
What is Y-Mabs Therapeutics’s market cap?
Y-Mabs Therapeutics’s market cap is $219.23M.
When is Y-Mabs Therapeutics’s upcoming earnings report date?
Y-Mabs Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 12 days.
How were Y-Mabs Therapeutics’s earnings last quarter?
Y-Mabs Therapeutics released its earnings results on May 13, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.212 by $0.092.
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does Y-Mabs Therapeutics have?
Y-Mabs Therapeutics has 45,295,795 shares outstanding.
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Y-Mabs Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.212. Following the earnings report the stock price went up 2.211%.
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Currently, no hedge funds are holding shares in YMAB
Y-Mabs Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.86 (188.15% Upside)
$13.86 (188.15% Upside)
Blogger Sentiment
Bullish
YMAB Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 12.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.87%
12-Months-Change
Fundamentals
Return on Equity
-29.93%
Trailing 12-Months
Asset Growth
-8.68%
Trailing 12-Months
Company Description
Y-Mabs Therapeutics
Y-Mabs Therapeutics, Inc. (YMAB) is a biopharmaceutical company focused on the development and commercialization of innovative antibody-based products for the treatment of cancer. The company specializes in developing therapies for pediatric oncology and orphan diseases, using its proprietary radioimmunotherapy platform aimed at targeting tumors with precision. Its lead product candidates target neuroblastoma, a rare cancer affecting children, as well as other solid tumor indications.
YMAB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments such as revenue growth in DANYELZA, especially internationally, and advancements in the Radiopharmaceutical segment. However, there were notable challenges like the significant decline in U.S. revenues and reduced R&D expenses. The sentiment is mixed with balanced highlights and lowlights.Read More>YMAB Stock 12 Month Forecast
Average Price Target
$13.86
▲(188.15%Upside)